The AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis
Part of paid clinical trials in Birmingham, Alabama.
- Sponsor
- Boehringer Ingelheim
- Study ID
- NCT06872892
- Phase
- PHASE3
- Status
- Recruiting
Conditions
- Bronchiectasis
Eligibility Criteria
- Sex
- ALL
- Age
- 12 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- BI 1291583 — DRUGBI 1291583
- Placebo matching BI 1291583 — DRUGPlacebo matching BI 1291583
Study Details
This study is open to adults and adolescents aged 12 to under 18 with bronchiectasis. People can participate in this study if they produce sputum and have had flare-ups (also called exacerbations). The purpose of this study is to find out whether a medicine called BI 1291583 helps people with bronchiectasis. Participants are put into 2 groups randomly, which means by chance. One group takes BI 1291583 tablets and the other group takes placebo tablets. A placebo tablet looks like the BI 1291583 tablet but does not contain any medicine. Participants take 1 tablet once a day for up to 1 year and 6 months. Participants are in the study for up to 1 year and 8 months. During this time, participants visit the study site up to 10 times and get about 13 phone calls from the site staff. Participants regularly complete a diary on a smartphone about their bronchiectasis symptoms and study doctors regularly check for any changes. The study doctors document when participants experience flare-ups. The number of flare-ups is compared between the participants who receive BI 1291583 and those who receive the placebo. The study doctors also regularly check participants' health and take note of any unwanted effects.
Key Dates
- First listed
- Mar 12, 2025
- Start date
- Jun 9, 2025
- Status verified
- Aug 2026
- Primary completion
- Jun 15, 2027
- Completion
- Dec 20, 2027
Study Design
- Enrollment
- 1,755 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: Treatment arm
- Placebo Comparator: Placebo arm
Primary Outcome Measure
Annualised rate of adjudicated pulmonary exacerbations (number of events per person year) up to Week 76 [ Time Frame: up to 76 weeks ]
Central Contacts
- Boehringer Ingelheim1-800-243-0127
Locations (80)
Find similar trials in Birmingham, AL
Related Studies
- Natural History of BronchiectasisRecruiting · National Heart, Lung, and Blood Institute (NHLBI) · Bethesda, Maryland
- Evaluation Of The Lung Microbiome In NTM BronchiectasisRecruiting · NYU Langone Health · New York, New York
- Hypertonic Saline in NCFBPHASE4 · Recruiting · University of North Carolina, Chapel Hill · Chapel Hill, North Carolina
- Acoustic Waveform Respiratory EvaluationRecruiting · Indiana University · Indianapolis, Indiana